Prestige Consumer Healthcare Inc. (NYSE:PBH) Given Average Rating of "Moderate Buy" by Analysts

Prestige Consumer Healthcare Inc. (NYSE:PBH - Get Free Report) has received an average rating of "Moderate Buy" from the six ratings firms that are covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $93.33.

PBH has been the topic of a number of research reports. Sidoti lowered Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price objective on the stock. in a report on Monday, December 9th. Raymond James upgraded shares of Prestige Consumer Healthcare to a "moderate buy" rating in a report on Thursday, December 19th. Canaccord Genuity Group lifted their price objective on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a "buy" rating in a research note on Friday, February 7th. DA Davidson increased their price objective on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a "buy" rating in a research note on Friday, February 7th. Finally, Oppenheimer raised their target price on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a report on Thursday, February 13th.

Prestige Consumer Healthcare Stock Down 0.3 %

Prestige Consumer Healthcare stock traded down $0.24 during midday trading on Wednesday, reaching $84.12. The company's stock had a trading volume of 640,928 shares, compared to its average volume of 258,829. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20. The stock has a market capitalization of $4.17 billion, a P/E ratio of 19.70, a PEG ratio of 2.69 and a beta of 0.46. The stock's 50-day simple moving average is $82.46 and its 200-day simple moving average is $78.59. Prestige Consumer Healthcare has a 52-week low of $62.35 and a 52-week high of $90.04.

Remove Ads

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.22 EPS for the quarter, beating the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. On average, sell-side analysts expect that Prestige Consumer Healthcare will post 4.5 EPS for the current year.

Insiders Place Their Bets

In related news, SVP Mary Beth Fritz sold 1,678 shares of the firm's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $90.00, for a total value of $151,020.00. Following the transaction, the senior vice president now directly owns 17,157 shares of the company's stock, valued at approximately $1,544,130. This trade represents a 8.91 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.60% of the stock is currently owned by company insiders.

Institutional Trading of Prestige Consumer Healthcare

A number of institutional investors have recently made changes to their positions in the company. Kestra Investment Management LLC purchased a new position in Prestige Consumer Healthcare in the 4th quarter valued at $27,000. CIBC Private Wealth Group LLC boosted its position in Prestige Consumer Healthcare by 48.9% during the fourth quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock worth $34,000 after acquiring an additional 152 shares during the last quarter. Headlands Technologies LLC purchased a new position in Prestige Consumer Healthcare in the 4th quarter worth approximately $40,000. Huntington National Bank boosted its holdings in shares of Prestige Consumer Healthcare by 39.9% during the 3rd quarter. Huntington National Bank now owns 635 shares of the company's stock worth $46,000 after purchasing an additional 181 shares during the last quarter. Finally, McIlrath & Eck LLC boosted its holdings in shares of Prestige Consumer Healthcare by 19.1% during the 4th quarter. McIlrath & Eck LLC now owns 959 shares of the company's stock worth $75,000 after purchasing an additional 154 shares during the last quarter. 99.95% of the stock is owned by institutional investors and hedge funds.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.